Advertisement

Doctors back bill to exempt CME from Open Payments reporting

By Adam Rubenfire  |  July 22, 2016

Roughly 100 national and state medical societies are backing a bill that would exempt drug and device makers from have to report payments made to doctors for participating in continuing medical education or receiving textbooks, journals and educational materials related to CME.

Costs of Zika among the many unknowns of the virus

Costs of Zika among the many unknowns of the virus

By Shannon Muchmore  |  July 20, 2016

History buffs and infectious-disease experts have already drawn links between the rubella outbreak in the 1960s and the current spread of Zika. But drugmakers today face greater regulatory hurdles, and the federal government has yet to dedicate funding to address the Zika epidemic.

Juno being sued over leukemia drug study

By Associated Press  |  July 13, 2016

Juno Therapeutics and its CEO, Hans E. Bishop, are being named in a lawsuit over whether the biotechnology company misled investors about the death of a patient in a key study involving its drug intended to treat leukemia.

D.C. educates providers, public about game-changing HIV-prevention drug

By Elizabeth Whitman  |  July 12, 2016

The HIV-prevention medication PrEP could help slash rates of infection, save hundreds of thousands of dollars in individual healthcare costs and save lives. Now, Washington, D.C., which has one of the highest rates of HIV infection in the U.S., is launching a campaign to bring light to this option.

Lower-cost biotech drug gets thumbs up from FDA panel

By Associated Press  |  July 12, 2016

AbbVie's Humira, the second-biggest selling drug in the world, could get some cheaper competition in the U.S., after a federal panel endorsed an alternative version of the pricey medication used to treat some inflammatory diseases.

FDA decision could impact competition for Amgen

By Steven Ross Johnson  |  July 09, 2016

Amgen is bracing for yet another drug to compete with its biologic medications. An FDA advisory panel is scheduled to consider approval Wednesday of a biosimilar created by Sandoz, Novartis' generic arm. The panel will advise the FDA, which makes the final call.

Juno halts midstage drug study over deaths

By Associated Press  |  July 08, 2016

Shares of Juno Therapeutics plunged more than 27% Friday, a day after halting a midstage study on a potential leukemia treatment following two patient deaths.

Advertisement
Modern Healthcare Daily

Award winning coverage of healthcare business and policy news.

The Modern Healthcare app includes a personalized home screen, strong search functionality and immediate downloads from the industry's leading healthcare media brand.